Reeves, Suzanne; Mahdi, Josef; Appleby, Matthew; Zubko, Olga; Lee, Teresa; Barber, Julie A; Liu, Kathy Y; ... Hallucinations working group, .; + view all Reeves, Suzanne; Mahdi, Josef; Appleby, Matthew; Zubko, Olga; Lee, Teresa; Barber, Julie A; Liu, Kathy Y; Taylor, John-Paul; Henderson, Emily J; Schrag, Anette; Howard, Robert; Weil, Rimona S; Hallucinations working group, .; - view fewer (2025) Minimal clinically important differences for treatment of hallucinations in Parkinson’s disease and dementia with Lewy bodies. Psychological Medicine , 55 , Article e93. 10.1017/S0033291725000534.

Preview	Text (Version of Record) Reeves_minimal-clinically-important-differences-for-treatment-of-hallucinations-in-parkinsons-disease-and-dementia-with-lewy-bodies.pdf Download (365kB) | Preview
Preview	Text Figure 1.jpg - Accepted Version Download (46kB) | Preview
Preview	Text Reeves_Table 1 Delphi survey expert clinicians.pdf Download (134kB) | Preview
Preview	Text Reeves_Table 2 case scenarios expert researchers.pdf Download (157kB) | Preview
Preview	Text Reeves_Table 3 Case scenarios Round 3.pdf Download (139kB) | Preview
Preview	Text Reeves_Table 4 Anchor and distribution based approaches.pdf Download (132kB) | Preview
Preview	Text Reeves_CHANGES TO Supplementary Information 1_Hallucinations working group names.pdf Download (99kB) | Preview

Abstract

Background: Hallucinations are common and distressing symptoms in Parkinson’s disease (PD). Treatment response in clinical trials is measured using validated questionnaires, including the Scale for Assessment of Positive Symptoms-Hallucinations (SAPS-H) and University of Miami PD Hallucinations Questionnaire (UM-PDHQ). The minimum clinically important difference (MCID) has not been determined for either scale. This study aimed to estimate a range of MCIDs for SAPS-H and UM-PDHQ using both consensus-based and statistical approaches. / / Methods: A Delphi survey was used to seek opinions of researchers, clinicians, and people with lived experience. We defined consensus as agreement ≥75%. Statistical approaches used blinded data from the first 100 PD participants in the Trial for Ondansetron as Parkinson’s Hallucinations Treatment (TOP HAT, NCT04167813). The distribution-based approach defined the MCID as 0.5 of the standard deviation of change in scores from baseline at 12 weeks. The anchor-based approach defined the MCID as the average change in scores corresponding to a 1-point improvement in clinical global impression-severity scale (CGI-S). / / Results: Fifty-one researchers and clinicians contributed to three rounds of the Delphi survey and reached consensus that the MCID was 2 points on both scales. Sixteen experts with lived experience reached the same consensus. Distribution-defined MCIDs were 2.6 points for SAPS-H and 1.3 points for UM-PDHQ, whereas anchor-based MCIDs were 2.1 and 1.3 points, respectively. / / Conclusions: We used triangulation from multiple methodologies to derive the range of MCID estimates for the two rating scales, which was between 2 and 2.7 points for SAPS-H and 1.3 and 2 points for UM-PDHQ.Methods: A Delphi survey was used to seek opinions of researchers, clinicians and people with lived experience. We defined consensus as agreement ≥75%. Statistical approaches used blinded data from the first 100 PD participants in the Trial for Ondansetron as Parkinson’s Hallucinations Treatment (TOP HAT, NCT04167813). The distribution-based approach defined the MCID as 0.5 of the standard deviation of change in scores from baseline at 12 weeks. The anchor-based approach defined the MCID as the average change in scores corresponding to a 1-point improvement in clinical global impression-severity scale (CGI-S). Results: Fifty-one researchers and clinicians contributed to three rounds of the Delphi survey and reached consensus that the MCID was 2 points on both scales. Sixteen experts with lived experience reached the same consensus. Distribution-defined MCIDs were 2.6 points for SAPS-H and 1.3 points for UM-PDHQ, whereas anchor-based MCIDs were 2.1 and 1.3 points, respectively.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item